Clinical trial · Interventional
Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases
A Phase II Study of Magnetic Resonance Guided and Monitored Interstitial Thermal Radiofrequency Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiofrequency ablation uses high-frequency electric current to heat and kill tumor cells. Magnetic resonance imaging-guided radiofrequency ablation may an effective treatment for primary kidney cancer, liver metastases, or other solid tumors. PURPOSE: Phase II trial to study the effectiveness of magnetic-resonance-guided radiofrequency ablation in treating patients who have primary kidney cancer, liver metastases, or other solid tumors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiofrequency ablation | Procedure | — | UNRESOLVED |
| thermal ablation therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Determine whether magnetic resonance image monitoring during radiofrequency interstitial thermal ablation can accurately predict complete destruction of focal tumor along with an adequate margin of normal tissue.
- timeFrame
- Patients are followed at 2 weeks and at 3, 6, 9, and 12 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of primary renal cell carcinoma, hepatic metastases, or other solid tumor meeting the following criteria:
* Not amenable to curative or substantial palliative therapy OR
* Failed chemotherapy or biological response modifier therapy OR
* Unlikely to benefit from conventional chemotherapy
* No more than 5 measurable metastatic masses in the liver
* No greater than 5 cm in diameter
* Other tumor sites allowed if location and size amenable to ablation therapy
* Measurable disease
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* More than 4 months
Hematopoietic:
* Granulocyte count at least 1,000/mm\^3
* Hemoglobin at least 8.0 g/dL
* Platelet count at least 100,000/mm\^3
* No untreated bleeding diathesis
Hepatic:
* PT no greater than 13.5 seconds
* PT/PTT normal if prior warfarin or heparin use
Renal:
* Not specified
Cardiovascular:
* No implanted pacemaker, incompatible aneurysm clip, or other device that would preclude magnetic resonance imaging
* No myocardial infarction within the past 6 weeks
* No unstable angina
Other:
* Not pregnant or nursing
* No serious active infection
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* See Disease Characteristics
* At least 28 days since prior biological response modifier therapy
Chemotherapy:
* See Disease Characteristics
* At least 28 days since prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* No prior radiotherapy to study lesion
Surgery:
* Not specified
Other:
* At least 7 days since prior nonsteroidal antiinflammatory drugs or aspirin
* At least 1 hour since prior heparin
* No concurrent warfarin
* No concurrent investigational drugsReferences
Publications (0)
Data not yet available